Contrast agent developer Molecular Biosystems of San Diego announced this month the resignation of Dr. Kenneth Widder as chairman of the board, effective immediately. The company said that Widder’s departure was part of an executive succession plan
Contrast agent developer Molecular Biosystems of San Diego announced this month the resignation of Dr. Kenneth Widder as chairman of the board, effective immediately. The company said that Widders departure was part of an executive succession plan that the company has been considering for some time. MBI has not named Widders replacement.
New Study Assesses Long-Term Outcomes of PSMA PET Use in PCa Recurrence Cases
October 24th 2024For patients with biochemical recurrence of prostate cancer, PSMA PET imaging may facilitate a 12.8 percent lower incidence of prostate cancer mortality in contrast to the combination of CT and bone scan, according to long-term outcome estimates from a new decision-analytic modeling study.
Can Diffusion MRI Predict Patient Response to Neoadjuvant Chemotherapy for Breast Cancer?
October 23rd 2024A model emphasizing time-dependent diffusion MRI was 15 percent more effective than apparent diffusion coefficient (ADC) measurements at predicting pathologic complete response to neoadjuvant chemotherapy for women with breast cancer, according to new research.